BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29644579)

  • 1. Comparison of Data on Serious Adverse Events and Mortality in ClinicalTrials.gov, Corresponding Journal Articles, and FDA Medical Reviews: Cross-Sectional Analysis.
    Pradhan R; Singh S
    Drug Saf; 2018 Sep; 41(9):849-857. PubMed ID: 29644579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles.
    Tang E; Ravaud P; Riveros C; Perrodeau E; Dechartres A
    BMC Med; 2015 Aug; 13():189. PubMed ID: 26269118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study.
    Hughes S; Cohen D; Jaggi R
    BMJ Open; 2014 Jul; 4(7):e005535. PubMed ID: 25009136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.
    Schwartz LM; Woloshin S; Zheng E; Tse T; Zarin DA
    Ann Intern Med; 2016 Sep; 165(6):421-30. PubMed ID: 27294570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis.
    de Vries YA; Roest AM; Beijers L; Turner EH; de Jonge P
    Eur Neuropsychopharmacol; 2016 Nov; 26(11):1752-1759. PubMed ID: 27659240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis.
    Chen KY; Borglund EM; Postema EC; Dunn AG; Bourgeois FT
    Clin Trials; 2022 Aug; 19(4):442-451. PubMed ID: 35482320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.
    Hartung DM; Zarin DA; Guise JM; McDonagh M; Paynter R; Helfand M
    Ann Intern Med; 2014 Apr; 160(7):477-83. PubMed ID: 24687070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals.
    Riveros C; Dechartres A; Perrodeau E; Haneef R; Boutron I; Ravaud P
    PLoS Med; 2013 Dec; 10(12):e1001566; discussion e1001566. PubMed ID: 24311990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
    Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
    BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics.
    Murphy DL; Lebin JA; Severtson SG; Olsen HA; Dasgupta N; Dart RC
    Drug Saf; 2018 Aug; 41(8):787-795. PubMed ID: 29582394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis.
    Yao Y; Liu Z; Zhang H; Li J; Peng Z; Yu J; Cao B; Shen L
    Front Pharmacol; 2021; 12():754858. PubMed ID: 34867369
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.
    Wang L; Rouse B; Marks-Anglin A; Duan R; Shi Q; Quach K; Chen Y; Cameron C; Schmid CH; Li T
    J Clin Epidemiol; 2019 Oct; 114():84-94. PubMed ID: 31226413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-drug interaction trials incompletely described drug interventions in ClinicalTrials.gov and published articles: an observational study.
    Jurić D; Bolić A; Pranić S; Marušić A
    J Clin Epidemiol; 2020 Jan; 117():126-137. PubMed ID: 31654788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles.
    Pranić S; Marušić A
    J Clin Epidemiol; 2016 Feb; 70():26-37. PubMed ID: 26226103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials.
    Federer C; Yoo M; Tan AC
    Assay Drug Dev Technol; 2016 Dec; 14(10):557-566. PubMed ID: 27631620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automatic extraction of quantitative data from ClinicalTrials.gov to conduct meta-analyses.
    Pradhan R; Hoaglin DC; Cornell M; Liu W; Wang V; Yu H
    J Clin Epidemiol; 2019 Jan; 105():92-100. PubMed ID: 30257185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.
    Withycombe B; Ovenell M; Meeker A; Ahmed SM; Hartung DM
    J Clin Epidemiol; 2016 Sep; 77():78-83. PubMed ID: 27108488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research without results: inadequate public reporting of clinical trial results.
    Gopal RK; Yamashita TE; Prochazka AV
    Contemp Clin Trials; 2012 May; 33(3):486-91. PubMed ID: 22342449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.